Risk reduction endpoints should be part of the design of adjuvant therapy clinical trials for patients with melanoma. A commentary.
Nathanson
L
L
School of Medicine, State University of New York, Stony Brook, New York, USA. larrymd@ix.netcom.com
D018890:Chemoprevention; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D012107:Research Design; D012307:Risk Factors